Drug Trial Radar · NCT06219941
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
226
Planned (sponsor's estimate)
Start
Dec 13, 2023
Primary completion
Nov 17, 2026
Study completion Jun 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
AZD0901Drug
Antibody-drug conjugate/Biologic
5-FluorouracilDrug
Chemotherapy agents
LeucovorinDrug
Chemotherapy agents
l-leucovorinDrug
Chemotherapy agents
IrinotecanDrug
Chemotherapy agents
Nanoliposomal IrinotecanDrug
Chemotherapy agents
GemcitabineDrug
Chemotherapy agents
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.Time frame: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
- Objective Response Rate (ORR).Time frame: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Locations
52 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Orange, California · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Santa Rosa, California · Recruiting
Research Site
Louisville, Kentucky · Recruiting
Research Site
Commack, New York · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Murdoch, Australia · Recruiting
Research Site
Randwick, Australia · Recruiting
Research Site
Kingston, Ontario, Canada · Withdrawn
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Sherbrooke, Quebec, Canada · Recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Tbilisi, Georgia · Recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Kitaadachi-gun, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Nagoya, Japan · Recruiting
Research Site
Osakasayama-shi, Japan · Recruiting
Research Site
George Town, Malaysia · Recruiting
Research Site
Johor Bahru, Malaysia · Completed
Research Site
Kuala Lumpur, Malaysia · Recruiting
Research Site
Kuala Selangor, Malaysia · Recruiting
Research Site
Kuching, Malaysia · Recruiting
Research Site
Chisinau, Moldova · Recruiting
Research Site
Krakow, Poland · Recruiting
Research Site
Warsaw, Poland · Recruiting
Research Site
Bukit Merah, Singapore · Recruiting
Research Site
Singapore, Singapore · Recruiting
Research Site
Singapore, Singapore · Recruiting
Research Site
Singapore, Singapore · Recruiting
Research Site
Gyeonggi-do, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.